Возможные риски при терапии тестостероном

Возможные риски при терапии тестостероном

Автор: Ефремов Е.А., Красняк С.С.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Андрология

Статья в выпуске: 1, 2017 года.

Бесплатный доступ

Гипогонадизм в настоящее время широко известен врачам и для его лечения все чаще назначается заместительная гормональная терапия (ЗГТ) тестостероном врачами общей практики, терапевтами, эндокринологами, урологами. Несмотря на то, что показанием к ЗГТ тестостероном является наличие низкого уровня тестостерона в совокупности с симптомами и признаками гипогонадизма, существуют некоторые разногласия в отношении возможных осложнений применения препаратов тестостерона и оценки преимуществ и рисков, связанных с тестостерон-заместительной терапией у этой категории пациентов. Широкий спектр преимуществ применения этого гормона для мужчин, которые включают в себя улучшение либидо и сексуальной функции, повышение плотности костной ткани, доли мышечной массы в составе тела, улучшение настроения и когнитивной функции и общего качества жизни позитивно воспринимается пациентами и лечащими врачами, однако, вопросы рисков и осложнений данной терапии остаются открытыми. Возможные риски включают, гепатотоксичность, эритроцитоз, апноэ сна и сердечно-сосудистую недостаточность. Целью данного обзора является обсуждение потенциальных рисков терапии мужчин препаратами тестостерона, необходимым мерам предосторожности и связанной тактике наблюдения.

Еще

Тестостерон, заместительная гормональная терапия, гипогонадизм, неблагоприятные реакции

Короткий адрес: https://sciup.org/142188181

IDR: 142188181

Список литературы Возможные риски при терапии тестостероном

  • Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18(1):5-15 DOI: 10.3109/13685538.2015.1004049
  • Tajar A, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR. EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS) J Clin Endocrinol Metab 2012;97:1508-16 DOI: 10.1210/jc.2011-2513
  • Huhtaniemi I. Late-onset hypogonadism: Current concepts and controversies of pathogenesis, diagnosis and treatment. Asian Journal of Andrology 2014; 16(2): 192-202 DOI: 10.4103/1008-682X.122336
  • Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010. Med J Aust 2012;196:642-5. doi: 10.5694/mja11.11277
  • Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ. EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35 DOI: 10.1056/NEJMoa0911101
  • Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009;21:1-8 DOI: 10.1038/ijir.2008.41
  • Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59 DOI: 10.1210/jc.2009-2354
  • Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, et al. EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013;168:445-55. doi: 10.1530/EJE-12-0890
  • Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92:3844-53 DOI: 10.1210/jc.2007-0620
  • Cunningham GR, Toma SM. Why is androgen replacement in males controversial? J Clin Endocrinol Metab 2011;96:38-52. doi: 10.1210/jc.2010-0266
  • Eisenberg ML. Testosterone Replacement Therapy and Prostate Cancer Incidence. The World Journal of Men’s Health 2015;33(3): 125-129 DOI: 10.5534/wjmh.2015.33.3.125
  • Morley JE, Perry HM, Kaiser FE. Effect of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41:149-152 DOI: 10.1111/j.1532-5415.1993.tb02049.x
  • Holmäng S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone-undecanoate treatment on prostatic volume and serum Prostate specific antigen in eugonadal middle-aged men. Prostate 1993;23:99-106.
  • Roehrborn CG, Siami P, Barkin J, Damiäo R, Major-Walker K, Nandy I, et al. CombAT Study Group: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123-131 DOI: 10.1016/j.eururo.2009.09.035
  • Liao CH, Li HY, Chung SD, Chiang HS, Yu HJ. Significant association between serum dihydrotestosterone level and prostate volume among Taiwanese men aged 40-79 years. Aging Male 2012; 15:28-33 DOI: 10.3109/13685538.2010.550660
  • Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and Prostate cancer: Current perspectives and future directions. Prostate 2002;52:213-235 DOI: 10.1002/pros.10108
  • Guo C, Gu W, Liu M, Peng BO, Yao X, Yang B et al. Efficacy and safety of testosterone replacement therapy in men with hypogonadism: A meta-analysis study of placebo-controlled trials. Exp and Therap Med 2016;11(3):853-863 DOI: 10.3892/etm.2015.2957
  • Raynaud JP, Gardette J, Rollet J, Legros JJ. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int 2013;111:880-890 DOI: 10.1111/j.1464-410X.2012.11514.x
  • Calof OM, Singh AB, Lee ML. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-1457.
  • Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24:299-311 DOI: 10.1002/j.1939-4640.2003.tb02676.x
  • Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5a-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993;77:375-381 DOI: 10.1210/jcem.77.2.7688377
  • Slater S, Oliver RTD. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17:431-439 DOI: 1170-229X/00/0012-0431
  • Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl 2002;25:119-125 DOI: 10.1046/j.1365-2605.2002.00335.x
  • Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Therapeutics and Clinical Risk Management 2009;5:427-448 DOI: 10.2147/TCRM.S3025
  • Wang C, Nieschlag E, Swerdloff R. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-514 DOI: 10.1530/EJE-08-0601
  • Blair IA. Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 2010;75:297-306 DOI: 10.1016/j.steroids.2010.01.012
  • Sun K, Liang GQ, Chen XF, Ping P, Yao WL, et al. Survey for late-onset hypogonadism among old and middle-aged males in Shanghai communities. Asian J Androl 2012;14:338-40 DOI: 10.1038/aja.2011.171
  • Curran MJ, Bihrle W., III Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999;53:423-424. doi: 10.1016/S0090-4295(98)00348-3.
  • Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol 1997;157:1845.
  • Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003; 170 (6pt1):2348-2351 DOI: 10.1097/01.ju.0000091104.71869.8e
  • Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5a-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993; 77:375-381 DOI: 10.1210/jcem.77.2.7688377
  • Slater S, Oliver RTD. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000;17:431-439 DOI: 1170-229X/00/0012-0431
  • Ferreira U, Leitao VA, Denardi F, Matheus WE, Stopiglia RM, Netto NR. Jr. Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients. Prostate Cancer Prostatic Dis 2006;9:39-41 DOI: 10.1038/sj.pcan.4500833
  • Weiss JM, Huang WY, Rinaldi S. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008;122(10):2345-2350 DOI: 10.1002/ijc.23326
  • Fowler JE, Jr, Whitmore WF., Jr Considerations for the use of testosterone with systemic chemotherapy in prostatic Cancer. Cancer 1982;49:1373-1377 DOI: 10.1016/j.urology.2010.09.058
  • Gurakar A, Caraceni P, Fagiuoli S, Van Thiel DH. Androgenic/anabolic steroid-induced intrahepatic cholestasis: a review with four additional case reports. J Okla State Med Assoc 1994;87:399-404 DOI: 10.1111/j.1572-0241.2006.00735.x
  • Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992;12:73-79. doi: 10.1111/j. 1600-0676.1992.tb00560.x
  • Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95:2560-75 DOI: 10.1111/j.2040-1124.2010.00046.x
  • The Endocrine Society Clinical bulletins in andropause: benefits and risks of treating hypogonadism in the aging male. Endocr Rep 2002;2:1-6.
  • Kim YC. Testosterone supplementation in the aging male. Int J Impot Res 1999;11:343-352.
  • Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol 2000;110:237-238 DOI: 10.1046/j.1365-2141.2000.02072-3.x
  • Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60(11):1451-1457.
  • Malkin CJ, Jones TH, Channer KS. Testosterone in chronic heart failure. Front Horm Res 2009;37:183-96 DOI: 10.1159/000176053
  • Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl 2012;14:428-35 DOI: 10.1038/aja.2012.21
  • Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22 DOI: 10.1056/NEJMoa1000485
  • Corona G G, Rastrelli G, Maseroli E, Sforza A, Maggi M. Testosterone Replacement Therapy and Cardiovascular Risk: A Review. World J Mens Health 2015;33(3):130-142 DOI: 10.5534/wjmh.2015.33.3.130
  • Bagatell CJ, Bremner WJ. Androgens in men -uses and abuses. N Engl J Med 1996;334:707-714 DOI: 10.1056/NEJM199603143341107
  • World Health Organization. Contraceptive efficacy of testosterone-induced azoospermia and oligozoopermia in normal men. Fertil Steril 1996;65:821.
  • Uzych L. Anabolic-androgenic steroids and psychiatric-related effects: a review. Can J Psychiatry 1992;37:23-28.
  • Bahrke MS, Yesalis CE, Wright JE. Psychological and behavioural ef fects of endogenous testosterone levels and anabolic-androgenic steroids among males: a review. Sports Med 1990;10:303-337
  • Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 2002;87:3394-3398. doi: 10.1210/jcem.87.7.8663
  • Schneider BK, Pickett CK, Zwillich CW. Influence of testosterone on breathing during sleep. J Appl Physiol 1986;61:618-623.
  • Matsumoto AM, Sandblom RE, Schoene RB. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985;22:713-721.
  • Tangredi JF, Buxton LL. Hypertension as a complication of topical testosterone therapy. Ann Pharmacother 2001;35:1205-1207 DOI: 10.1345/aph.1A020
  • Von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002; 23:419-425. doi: 10.1002/j.1939-4640.2002.tb02249.x
  • De Ronde W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009;24(2):425-428 DOI: 10.1093/humrep/den372
  • Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ. Zinc status and serum testosterone levels of healthy adults. Nutrition 1996 May;12(5):344-8.
  • Oluboyo AO, Adijeh RU, Onyenekwe CC, Oluboyo BO, Mbaeri TC, et al. Relationship between serum levels of testosterone, zinc and selenium in infertile males attending fertility clinic in Nnewi, south east Nigeria. Afr J Med Med Sci 2012 Dec;41 Suppl:51-4.
  • Zanatta L, Zamoner A, Gonçalves R, Zanatta AP, Bouraïma-Lelong H. Effect of 1a, 25-dihydroxyvitamin D 3 in plasma membrane targets in immature rat testis: Ionic channels and gamma-glutamyl transpeptidase activity. Arch Biochem Biophys 515: 46-53 DOI: 10.1016/j.abb.2011.09.001
  • Nimptsch K, Platz EA, Willett WC, Giovannucci E. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf) 77: 106-112 DOI: 10.1111/j.1365-2265.2012.04332.x
  • Wehr E, Pilz S, Boehm BO, März W, Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf) 73: 243-248 DOI: 10.1111/j.1365-2265.2009.03777.x
  • Gunnels TA, Bloomer RJ. Increasing Circulating Testosterone: Impact of Herbal Dietary Supplements. J Plant Biochem Physiol 2:130 DOI: 10.4172/2329-9029.1000130
  • George A. and Henkel R. Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy. Andrologia 46: 708-721 DOI: 10.1111/and.12214
  • Tong KL, Chan KL, AbuBakar S, Low BS, Ma HQ, Wong PF. The In Vitro and In Vivo Anti-Cancer Activities of a Standardized Quassinoids Composition fromEurycoma longifolia on LNCaP Human Prostate Cancer Cells. PLoS ONE 2015;10(3):e0121752. pone.0121752 DOI: 10.1371/journal
  • Topo E, Soricelli A, D’Aniello A, Ronsini S, D’Aniello G. The role and molecular mechanism of D-aspartic acid in the release and synthesis of LH and testosterone in humans and rats. Reprod Biol Endocrinol 2009 Oct 27;7:120 DOI: 10.1186/1477-7827-7-120
  • Willoughby DS, Leutholtz B. D-aspartic acid supplementation combined with 28 days of heavy resistance training has no effect on body composition, muscle strength, and serum hormones associated with the hypothalamo-pituitary-gonadal axis in resistance-trained men. Nutr Res 2013 Oct; 33(10):803-10 DOI: 10.1016/j.nutres.2013.07.010
Еще
Статья научная
SciUp 2024 © 2024 ©